|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: STK35 |
Gene summary for STK35 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | STK35 | Gene ID | 140901 |
| Gene name | serine/threonine kinase 35 | |
| Gene Alias | CLIK1 | |
| Cytomap | 20p13 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q8TDR2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 140901 | STK35 | LZE7T | Human | Esophagus | ESCC | 2.83e-04 | 1.24e-01 | 0.0667 |
| 140901 | STK35 | LZE20T | Human | Esophagus | ESCC | 4.12e-05 | 1.12e-01 | 0.0662 |
| 140901 | STK35 | LZE24T | Human | Esophagus | ESCC | 8.47e-09 | 1.18e-01 | 0.0596 |
| 140901 | STK35 | P1T-E | Human | Esophagus | ESCC | 1.16e-05 | 3.12e-01 | 0.0875 |
| 140901 | STK35 | P2T-E | Human | Esophagus | ESCC | 2.16e-07 | 1.13e-01 | 0.1177 |
| 140901 | STK35 | P4T-E | Human | Esophagus | ESCC | 4.21e-11 | 1.10e-01 | 0.1323 |
| 140901 | STK35 | P8T-E | Human | Esophagus | ESCC | 7.34e-17 | 2.43e-01 | 0.0889 |
| 140901 | STK35 | P10T-E | Human | Esophagus | ESCC | 1.17e-20 | 1.94e-01 | 0.116 |
| 140901 | STK35 | P11T-E | Human | Esophagus | ESCC | 1.18e-02 | 1.55e-01 | 0.1426 |
| 140901 | STK35 | P12T-E | Human | Esophagus | ESCC | 8.15e-11 | 1.29e-01 | 0.1122 |
| 140901 | STK35 | P15T-E | Human | Esophagus | ESCC | 2.25e-15 | 1.28e-01 | 0.1149 |
| 140901 | STK35 | P16T-E | Human | Esophagus | ESCC | 3.61e-07 | 9.85e-02 | 0.1153 |
| 140901 | STK35 | P17T-E | Human | Esophagus | ESCC | 1.91e-02 | 1.38e-01 | 0.1278 |
| 140901 | STK35 | P20T-E | Human | Esophagus | ESCC | 2.43e-04 | 2.23e-02 | 0.1124 |
| 140901 | STK35 | P21T-E | Human | Esophagus | ESCC | 1.47e-17 | 1.68e-01 | 0.1617 |
| 140901 | STK35 | P22T-E | Human | Esophagus | ESCC | 1.48e-13 | 7.93e-02 | 0.1236 |
| 140901 | STK35 | P23T-E | Human | Esophagus | ESCC | 2.79e-11 | 2.10e-01 | 0.108 |
| 140901 | STK35 | P24T-E | Human | Esophagus | ESCC | 2.32e-11 | 6.67e-02 | 0.1287 |
| 140901 | STK35 | P26T-E | Human | Esophagus | ESCC | 3.14e-73 | 1.17e+00 | 0.1276 |
| 140901 | STK35 | P27T-E | Human | Esophagus | ESCC | 2.02e-06 | 6.07e-02 | 0.1055 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| STK35 | SNV | Missense_Mutation | novel | c.1255N>T | p.Asp419Tyr | p.D419Y | Q8TDR2 | protein_coding | deleterious(0) | benign(0.27) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
| STK35 | SNV | Missense_Mutation | novel | c.1594T>G | p.Cys532Gly | p.C532G | Q8TDR2 | protein_coding | deleterious_low_confidence(0) | benign(0.076) | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
| STK35 | SNV | Missense_Mutation | rs138789925 | c.1196N>G | p.Asn399Ser | p.N399S | Q8TDR2 | protein_coding | tolerated(0.38) | benign(0.023) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
| STK35 | SNV | Missense_Mutation | novel | c.744N>A | p.Phe248Leu | p.F248L | Q8TDR2 | protein_coding | tolerated(0.27) | benign(0.055) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| STK35 | SNV | Missense_Mutation | c.1577G>T | p.Arg526Ile | p.R526I | Q8TDR2 | protein_coding | deleterious(0) | possibly_damaging(0.81) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| STK35 | SNV | Missense_Mutation | novel | c.1322N>T | p.Gly441Val | p.G441V | Q8TDR2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A27L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin+cuclophosphamide | SD |
| STK35 | SNV | Missense_Mutation | c.1495N>G | p.Ser499Ala | p.S499A | Q8TDR2 | protein_coding | tolerated(0.06) | benign(0.18) | TCGA-E9-A1ND-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD | |
| STK35 | insertion | Nonsense_Mutation | novel | c.1595_1596insCAGCAGGCCTAGGGAGAGGGATCACTTCAAATAGGAATAGCC | p.Cys532_Ala533insSerArgProArgGluArgAspHisPheLysTerGluTerPro | p.C532_A533insSRPRERDHFK*E*P | Q8TDR2 | protein_coding | TCGA-A2-A0CT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD | ||
| STK35 | insertion | Nonsense_Mutation | novel | c.1471_1472insGTGTCATACCTTAGAAAGGCACTCAGTGCCAGTTGTGCAGGT | p.Pro491delinsArgValIleProTerLysGlyThrGlnCysGlnLeuCysArgSer | p.P491delinsRVIP*KGTQCQLCRS | Q8TDR2 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| STK35 | SNV | Missense_Mutation | c.926N>A | p.Cys309Tyr | p.C309Y | Q8TDR2 | protein_coding | tolerated(0.3) | benign(0.115) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |